Author:
Zhou Qing,Chen Xiao-Yuan,Yang Zhi-Min,Wu Yi-Long
Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. National Center for Drug Evaluation (CDE). 2014 Annual Report on Drug Evaluation in China. Yao xue Jin Zhan [Progress In Pharmaceutical Sciences] 39, 241–250 (2015).
2. China Food and Drug Administration. Guidelines for electronic data collection techniques in clinical trials. sda.gov.cn http://www.sda.gov.cn/WS01/CL0087/160963.html (in Chinese) (2016).
3. China Food and Drug Administration. Administrative measures for drug registration. eng.sfda.gov.cn http://eng.sfda.gov.cn/WS03/CL0768/61645.html (2007).
4. Li, J. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34, 1448–1454 (2016).
5. Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662 (2015).
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献